Search
forLearn
5 / 801 resultslearn Stem Cell Factor
learn zinc PCA
learn SCUBE3
a signaling molecule from dermal papilla cells being actively researched
learn Osteopontin
signaling protein that, when suppressed, may grow hair by reducing inflammation and stem cell loss
Research
5 / 282 resultsresearch Temporal Dynamics of Endothelium After Radiation Injury Reveal a Transient Pro-Angiogenic Capillary Subpopulation Associated with Skin Repair
A temporary capillary cell type helps skin repair after radiation by promoting blood vessel growth.
research Regulatory effect of 4-O-methylhonokiol on TGF-β1-induced cell cycle arrest in human keratinocyte cell line (HaCaT)
4-O-methylhonokiol from Magnolia Officinalis may promote hair growth by interfering with TGF-β1 effects in skin cells.
research Exploring the Drug Repurposing Versatility of Valproic Acid as a Multifunctional Regulator of Innate and Adaptive Immune Cells
Valproic Acid could potentially be used to treat immune-related conditions due to its ability to modify immune cell functions.
research The Proximal Promoter of the Human Transglutaminase 3 Gene
The TGM3 gene's promoter region is key for skin and hair cell function and may aid gene therapy.
research The Tissue-dependent Keratin 19 Gene Transcription Is Regulated by GKLF/KLF4 and Sp1
GKLF/KLF4 and Sp1 control Keratin 19 gene activity, influencing cancer-related changes.
Community Join
5 / 1000+ resultscommunity Why doesn't phase 3 of PP405 start straight away?
Pelage is delaying the start of phase 3 trials for PP405 to 2026 due to necessary regulatory processes, despite having $120 million in funding. Users discuss the potential of PP405 for hair regrowth, with some expressing skepticism and others hopeful for new treatments like Breezula.
community US FDA will now default to only one clinical trial for drug applications, will this accelerate the release of PP405 and other drugs in clinical trials?
The FDA will now require only one clinical trial for drug approval, potentially speeding up the release of hair loss treatments like PP405. Pelage is expected to present full results of PP405 Phase 2a trials and move to Phase III in mid-2026.
community PP405 2a study was a safety study. Some rational explaining.
The conversation discusses the safety study of PP405, emphasizing that early trials focus on safety rather than efficacy, and that any efficacy data from such a short study should be viewed skeptically. It also highlights that the information released is primarily for securing funding, and that meaningful efficacy results are expected in later phases.
community Are we still getting the PP405 phase 2a results by the end of March?
People are discussing the anticipated release of PP405 phase 2a results, expected by the end of March, with some skepticism about its effectiveness. There is cautious optimism due to past experiences with similar treatments like Breezula, despite concerns about the lack of presentation at the AAD 2026 conference.
community HMI 115 Phase 1 update: Changes to clinicaltrials.gov page
A Phase 1 update for the HMI 115 clinical trial, which involves 16 participants and is expected to end in July 2023; as well as changes to the recruitment process, including treatment protocols with Minoxidil, Finasteride, and RU58841.